{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T18:57:38Z","timestamp":1783105058103,"version":"3.54.6"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-22302-w","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:21:39Z","timestamp":1762161699000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Preclinical efficacy and mechanisms of statin-loaded polymeric nanocapsules: a meta-analysis of tumor lipid metabolism inhibition"],"prefix":"10.1038","volume":"15","author":[{"given":"Changing","family":"lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aolin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renyang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xintao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"22302_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144, 646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013 (2011).","journal-title":"Cell"},{"key":"22302_CR2","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.devcel.2021.04.013","volume":"56","author":"LA Broadfield","year":"2021","unstructured":"Broadfield, L. A., Pane, A. A., Talebi, A., Swinnen, J. V. & Fendt, S. M. Lipid metabolism in cancer: New perspectives and emerging mechanisms. Dev. Cell 56, 1363\u20131393. https:\/\/doi.org\/10.1016\/j.devcel.2021.04.013 (2021).","journal-title":"Dev. Cell"},{"key":"22302_CR3","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201606","author":"X Bian","year":"2021","unstructured":"Bian, X. et al. Lipid metabolism and cancer. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20201606 (2021).","journal-title":"J. Exp. Med."},{"issue":"525\u2013538","key":"22302_CR4","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/j.cmet.2019.06.014","volume":"30","author":"J Bi","year":"2019","unstructured":"Bi, J. et al. Oncogene amplification in growth factor signaling pathways renders cancers dependent on membrane lipid remodeling. Cell Metab 30(525\u2013538), e528. https:\/\/doi.org\/10.1016\/j.cmet.2019.06.014 (2019).","journal-title":"Cell Metab"},{"key":"22302_CR5","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1158\/2159-8290.CD-19-0061","volume":"9","author":"RC Gimple","year":"2019","unstructured":"Gimple, R. C. et al. Glioma stem cell-specific superenhancer promotes polyunsaturated fatty-acid synthesis to support EGFR signaling. Cancer Discov. 9, 1248\u20131267. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0061 (2019).","journal-title":"Cancer Discov."},{"key":"22302_CR6","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1038\/s41388-017-0093-z","volume":"37","author":"A Ladanyi","year":"2018","unstructured":"Ladanyi, A. et al. Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene 37, 2285\u20132301. https:\/\/doi.org\/10.1038\/s41388-017-0093-z (2018).","journal-title":"Oncogene"},{"key":"22302_CR7","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2217\/fon.10.11","volume":"6","author":"R Flavin","year":"2010","unstructured":"Flavin, R., Peluso, S., Nguyen, P. L. & Loda, M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 6, 551\u2013562. https:\/\/doi.org\/10.2217\/fon.10.11 (2010).","journal-title":"Future Oncol."},{"key":"22302_CR8","first-page":"219","volume":"9","author":"X Ding","year":"2019","unstructured":"Ding, X., Zhang, W., Li, S. & Yang, H. The role of cholesterol metabolism in cancer. Am. J. Cancer Res. 9, 219\u2013227 (2019).","journal-title":"Am. J. Cancer Res."},{"key":"22302_CR9","doi-asserted-by":"publisher","first-page":"e2202956","DOI":"10.1002\/advs.202202956","volume":"10","author":"J Li","year":"2023","unstructured":"Li, J. et al. Tumor cell-intrinsic CD96 mediates chemoresistance and cancer stemness by regulating mitochondrial fatty acid beta-oxidation. Adv. Sci. (Weinh) 10, e2202956. https:\/\/doi.org\/10.1002\/advs.202202956 (2023).","journal-title":"Adv. Sci. (Weinh)"},{"key":"22302_CR10","doi-asserted-by":"publisher","first-page":"8117","DOI":"10.1158\/0008-5472.CAN-09-3871","volume":"70","author":"E Rysman","year":"2010","unstructured":"Rysman, E. et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 70, 8117\u20138126. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-3871 (2010).","journal-title":"Cancer Res."},{"key":"22302_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13045-023-01498-2","volume":"16","author":"HR Jin","year":"2023","unstructured":"Jin, H. R. et al. Lipid metabolic reprogramming in tumor microenvironment: From mechanisms to therapeutics. J. Hematol. Oncol. 16, 103. https:\/\/doi.org\/10.1186\/s13045-023-01498-2 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"22302_CR12","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1158\/0008-5472.CAN-20-1954","volume":"81","author":"LA Broadfield","year":"2021","unstructured":"Broadfield, L. A. et al. Fat induces glucose metabolism in nontransformed liver cells and promotes liver tumorigenesis. Cancer Res. 81, 1988\u20132001. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-1954 (2021).","journal-title":"Cancer Res."},{"key":"22302_CR13","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1038\/onc.2012.6","volume":"31","author":"JW Clendening","year":"2012","unstructured":"Clendening, J. W. & Penn, L. Z. Targeting tumor cell metabolism with statins. Oncogene 31, 4967\u20134978. https:\/\/doi.org\/10.1038\/onc.2012.6 (2012).","journal-title":"Oncogene"},{"key":"22302_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2174\/156800906775471743","volume":"6","author":"KM Swanson","year":"2006","unstructured":"Swanson, K. M. & Hohl, R. J. Anti-cancer therapy: Targeting the mevalonate pathway. Curr. Cancer Drug. Targets. 6, 15\u201337. https:\/\/doi.org\/10.2174\/156800906775471743 (2006).","journal-title":"Curr. Cancer Drug. Targets."},{"key":"22302_CR15","doi-asserted-by":"publisher","first-page":"5791","DOI":"10.1158\/1078-0432.CCR-20-1967","volume":"26","author":"J Longo","year":"2020","unstructured":"Longo, J., van Leeuwen, J. E., Elbaz, M., Branchard, E. & Penn, L. Z. Statins as anticancer agents in the era of precision medicine. Clin. Cancer Res. 26, 5791\u20135800. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1967 (2020).","journal-title":"Clin. Cancer Res."},{"key":"22302_CR16","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1053\/j.gastro.2009.01.053","volume":"136","author":"HB El-Serag","year":"2009","unstructured":"El-Serag, H. B., Johnson, M. L., Hachem, C. & Morgana, R. O. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 136, 1601\u20131608. https:\/\/doi.org\/10.1053\/j.gastro.2009.01.053 (2009).","journal-title":"Gastroenterology"},{"key":"22302_CR17","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1136\/gut.2009.190900","volume":"59","author":"M Bardou","year":"2010","unstructured":"Bardou, M., Barkun, A. & Martel, M. Effect of statin therapy on colorectal cancer. Gut 59, 1572\u20131585. https:\/\/doi.org\/10.1136\/gut.2009.190900 (2010).","journal-title":"Gut"},{"key":"22302_CR18","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1158\/1055-9965.EPI-07-0599","volume":"16","author":"TJ Murtola","year":"2007","unstructured":"Murtola, T. J., Tammela, T. L., Lahtela, J. & Auvinen, A. Cholesterol-lowering drugs and prostate cancer risk: A population-based case-control study. Cancer Epidemiol. Biomarkers Prev. 16, 2226\u20132232. https:\/\/doi.org\/10.1158\/1055-9965.EPI-07-0599 (2007).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"22302_CR19","doi-asserted-by":"publisher","first-page":"8707","DOI":"10.1158\/0008-5472.CAN-05-4061","volume":"66","author":"MJ Campbell","year":"2006","unstructured":"Campbell, M. J. et al. Breast cancer growth prevention by statins. Cancer Res. 66, 8707\u20138714. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-4061 (2006).","journal-title":"Cancer Res."},{"key":"22302_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s12032-023-02248-7","volume":"41","author":"SA Dewidar","year":"2023","unstructured":"Dewidar, S. A., Hamdy, O., Soliman, M. M., El Gayar, A. M. & El-Mesery, M. Enhanced therapeutic efficacy of doxorubicin\/cyclophosphamide in combination with pitavastatin or simvastatin against breast cancer cells. Med. Oncol. 41, 7. https:\/\/doi.org\/10.1007\/s12032-023-02248-7 (2023).","journal-title":"Med. Oncol."},{"key":"22302_CR21","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/j.2042-7158.2011.01273.x","volume":"63","author":"R Tiwari","year":"2011","unstructured":"Tiwari, R. & Pathak, K. Statins therapy: A review on conventional and novel formulation approaches. J. Pharm. Pharmacol. 63, 983\u2013998. https:\/\/doi.org\/10.1111\/j.2042-7158.2011.01273.x (2011).","journal-title":"J. Pharm. Pharmacol."},{"key":"22302_CR22","doi-asserted-by":"publisher","first-page":"76514","DOI":"10.1007\/s11356-022-23043-3","volume":"29","author":"S Singh","year":"2022","unstructured":"Singh, S. et al. Insights into the pivotal role of statins and its nanoformulations in hyperlipidemia. Environ. Sci. Pollut. Res. Int. 29, 76514\u201376531. https:\/\/doi.org\/10.1007\/s11356-022-23043-3 (2022).","journal-title":"Environ. Sci. Pollut. Res. Int."},{"key":"22302_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11912-021-01023-z","volume":"23","author":"N Joharatnam-Hogan","year":"2021","unstructured":"Joharatnam-Hogan, N. et al. Statins as potential chemoprevention or therapeutic agents in cancer: A model for evaluating repurposed drugs. Curr. Oncol. Rep. 23, 29. https:\/\/doi.org\/10.1007\/s11912-021-01023-z (2021).","journal-title":"Curr. Oncol. Rep."},{"key":"22302_CR24","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1080\/01443615.2022.2033964","volume":"42","author":"M El Sabeh","year":"2022","unstructured":"El Sabeh, M. et al. Simvastatin-loaded liposome nanoparticles treatment for uterine leiomyoma in a patient-derived xenograft mouse model: A pilot study. J. Obstet. Gynaecol. 42, 2139\u20132143. https:\/\/doi.org\/10.1080\/01443615.2022.2033964 (2022).","journal-title":"J. Obstet. Gynaecol."},{"key":"22302_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","volume":"160","author":"Y Barenholz","year":"2012","unstructured":"Barenholz, Y. Doxil(R)\u2013the first FDA-approved nano-drug: Lessons learned. J. Control. Release. 160, 117\u2013134. https:\/\/doi.org\/10.1016\/j.jconrel.2012.03.020 (2012).","journal-title":"J. Control. Release."},{"key":"22302_CR26","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3389\/fonc.2020.00591","volume":"10","author":"E Pan","year":"2020","unstructured":"Pan, E., Bogumil, D., Cortessis, V., Yu, S. & Nieva, J. A Systematic review of the efficacy of preclinical models of lung cancer drugs. Front. Oncol. 10, 591. https:\/\/doi.org\/10.3389\/fonc.2020.00591 (2020).","journal-title":"Front. Oncol."},{"key":"22302_CR27","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jconrel.2016.04.028","volume":"232","author":"GH Petersen","year":"2016","unstructured":"Petersen, G. H., Alzghari, S. K., Chee, W., Sankari, S. S. & La-Beck, N. M. Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin. J. Control Release 232, 255\u2013264. https:\/\/doi.org\/10.1016\/j.jconrel.2016.04.028 (2016).","journal-title":"J. Control Release"},{"key":"22302_CR28","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1097\/j.pain.0000000000001974","volume":"161","author":"N Soliman","year":"2020","unstructured":"Soliman, N., Rice, A. S. C. & Vollert, J. A practical guide to preclinical systematic review and meta-analysis. Pain 161, 1949\u20131954. https:\/\/doi.org\/10.1097\/j.pain.0000000000001974 (2020).","journal-title":"Pain"},{"key":"22302_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 372, n71. https:\/\/doi.org\/10.1136\/bmj.n71 (2021).","journal-title":"BMJ"},{"key":"22302_CR30","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jneumeth.2013.09.010","volume":"221","author":"HM Vesterinen","year":"2014","unstructured":"Vesterinen, H. M. et al. Meta-analysis of data from animal studies: A practical guide. J. Neurosci. Methods 221, 92\u2013102. https:\/\/doi.org\/10.1016\/j.jneumeth.2013.09.010 (2014).","journal-title":"J. Neurosci. Methods"},{"key":"22302_CR31","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg, C. B. & Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 1088\u20131101 (1994).","journal-title":"Biometrics"},{"key":"22302_CR32","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger, M., Davey Smith, G., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629 (1997).","journal-title":"BMJ"},{"key":"22302_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-2288-14-43","volume":"14","author":"CR Hooijmans","year":"2014","unstructured":"Hooijmans, C. R. et al. SYRCLE\u2019s risk of bias tool for animal studies. BMC Med. Res. Methodol. 14, 43. https:\/\/doi.org\/10.1186\/1471-2288-14-43 (2014).","journal-title":"BMC Med. Res. Methodol."},{"key":"22302_CR34","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jconrel.2024.09.018","volume":"375","author":"H Tan","year":"2024","unstructured":"Tan, H. et al. Endoplasmic reticulum-targeted biomimetic nanoparticles induce apoptosis and ferroptosis by regulating endoplasmic reticulum function in colon cancer. J. Control Release 375, 422\u2013437. https:\/\/doi.org\/10.1016\/j.jconrel.2024.09.018 (2024).","journal-title":"J. Control Release"},{"key":"22302_CR35","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jconrel.2024.10.013","volume":"376","author":"LA Heikal","year":"2024","unstructured":"Heikal, L. A. et al. Microneedles integrated with atorvastatin-loaded pumpkisomes for breast cancer therapy: A localized delivery approach. J. Control Release 376, 354\u2013368. https:\/\/doi.org\/10.1016\/j.jconrel.2024.10.013 (2024).","journal-title":"J. Control Release"},{"key":"22302_CR36","doi-asserted-by":"publisher","first-page":"6689","DOI":"10.1021\/acsami.4c17858","volume":"17","author":"J Zhang","year":"2025","unstructured":"Zhang, J. et al. Core-shell nanoparticles with sequential drug release depleting cholesterol for reverse tumor multidrug resistance. ACS Appl. Mater. Interfaces 17, 6689\u20136702. https:\/\/doi.org\/10.1021\/acsami.4c17858 (2025).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"22302_CR37","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.2147\/IJN.S455427","volume":"19","author":"S Pang","year":"2024","unstructured":"Pang, S. et al. Synergistic effect of layered double hydroxides nanodosage form to induce apoptosis and ferroptosis in breast cancer. Int. J. Nanomed. 19, 4199\u20134215. https:\/\/doi.org\/10.2147\/IJN.S455427 (2024).","journal-title":"Int. J. Nanomed."},{"key":"22302_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202302752","volume":"13","author":"N Yang","year":"2024","unstructured":"Yang, N. et al. Biomimetic nanoarchitectonics with chitosan nanogels for collaborative induction of ferroptosis and anticancer immunity for cancer therapy. Adv. Healthc. Mater. 13, e2302752. https:\/\/doi.org\/10.1002\/adhm.202302752 (2024).","journal-title":"Adv. Healthc. Mater."},{"key":"22302_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpx.2024.100249","volume":"7","author":"DM Gaber","year":"2024","unstructured":"Gaber, D. M. et al. A drug repurposing approach of Atorvastatin calcium for its antiproliferative activity for effective treatment of breast cancer: In vitro and in vivo assessment. Int. J. Pharm. X 7, 100249. https:\/\/doi.org\/10.1016\/j.ijpx.2024.100249 (2024).","journal-title":"Int. J. Pharm. X"},{"key":"22302_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.870347","volume":"13","author":"G Negrea","year":"2022","unstructured":"Negrea, G. et al. Active tumor-targeting nano-formulations containing simvastatin and doxorubicin inhibit melanoma growth and angiogenesis. Front. Pharmacol. 13, 870347. https:\/\/doi.org\/10.3389\/fphar.2022.870347 (2022).","journal-title":"Front. Pharmacol."},{"key":"22302_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2023.148069","author":"Q Yao","year":"2024","unstructured":"Yao, Q. et al. Modulation of glucose metabolism through macrophage-membrane-coated metal-organic framework nanoparticles for triple-negative breast cancer therapy. Chem. Eng. J. https:\/\/doi.org\/10.1016\/j.cej.2023.148069 (2024).","journal-title":"Chem. Eng. J."},{"key":"22302_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2022.103479","author":"S Unnam","year":"2022","unstructured":"Unnam, S., Manjappa, A. S., Eswara, B. R. M., Salawi, A. & Gunti, P. Liposomal Melphalan: Approach to obtain improved plasma stability, pharmacokinetics, and in vitro and in vivo anticancer efficacy in combination with liposomal simvastatin against mouse RPMI-8226 multiple myeloma model. J. Drug Deliv. Sci. Technol. https:\/\/doi.org\/10.1016\/j.jddst.2022.103479 (2022).","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"22302_CR43","first-page":"1255","volume":"11","author":"N Li","year":"2019","unstructured":"Li, N. et al. Herceptin-conjugated liposomes co-loaded with doxorubicin and simvastatin in targeted prostate cancer therapy. Am. J. Trans. Res. 11, 1255\u20131269 (2019).","journal-title":"Am. J. Trans. Res."},{"key":"22302_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2023.113316","volume":"226","author":"D Marwaha","year":"2023","unstructured":"Marwaha, D. et al. Synergistic delivery of Imatinib through multifunctional nano-crystalline capsules, in response to redox environment for improved breast cancer therapy. Colloids Surf B Biointerfaces 226, 113316. https:\/\/doi.org\/10.1016\/j.colsurfb.2023.113316 (2023).","journal-title":"Colloids Surf B Biointerfaces"},{"key":"22302_CR45","doi-asserted-by":"publisher","first-page":"885","DOI":"10.2147\/ijn.S88546","volume":"11","author":"IF Kretzer","year":"2016","unstructured":"Kretzer, I. F., Maria, D. A., Guido, M. C., Contente, T. C. & Maranh\u00e3o, R. C. Simvastatin increases the antineoplastic actions of paclitaxel carried in lipid nanoemulsions in melanoma-bearing mice. Int. J. Nanomed. 11, 885\u2013904. https:\/\/doi.org\/10.2147\/ijn.S88546 (2016).","journal-title":"Int. J. Nanomed."},{"key":"22302_CR46","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.2147\/dddt.S256636","volume":"14","author":"H Bao","year":"2020","unstructured":"Bao, H., Zheng, N., Li, Z. & Zhi, Y. Synergistic effect of tangeretin and atorvastatin for colon cancer combination therapy: targeted delivery of these dual drugs using RGD peptide decorated nanocarriers. Drug. Des. Devel. Ther. 14, 3057\u20133068. https:\/\/doi.org\/10.2147\/dddt.S256636 (2020).","journal-title":"Drug. Des. Devel. Ther."},{"key":"22302_CR47","doi-asserted-by":"publisher","first-page":"29385","DOI":"10.1021\/acsami.8b11723","volume":"10","author":"N Zhang","year":"2018","unstructured":"Zhang, N. et al. Loading lovastatin into camptothecin-floxuridine conjugate nanocapsules for enhancing anti-metastatic efficacy of cocktail chemotherapy on triple-negative breast cancer. ACS Appl. Mater. Interfaces 10, 29385\u201329397. https:\/\/doi.org\/10.1021\/acsami.8b11723 (2018).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"22302_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202102799","author":"J Yang","year":"2022","unstructured":"Yang, J. et al. Metabolic intervention nanoparticles for triple-negative breast cancer therapy via overcoming FSP1-mediated ferroptosis resistance. Adv. Healthcare Mater. https:\/\/doi.org\/10.1002\/adhm.202102799 (2022).","journal-title":"Adv. Healthcare Mater."},{"key":"22302_CR49","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1166\/jbn.2015.2068","volume":"11","author":"Y Wu","year":"2015","unstructured":"Wu, Y. et al. Novel simvastatin-loaded nanoparticles based on cholic acid-core star-shaped PLGA for breast cancer treatment. J. Biomed. Nanotechnol. 11, 1247\u20131260. https:\/\/doi.org\/10.1166\/jbn.2015.2068 (2015).","journal-title":"J. Biomed. Nanotechnol."},{"key":"22302_CR50","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jconrel.2018.08.012","volume":"287","author":"X Mo","year":"2018","unstructured":"Mo, X. et al. Antiglioma via regulating oxidative stress and remodeling tumor-associated macrophage using lactoferrin-mediated biomimetic codelivery of simvastatin\/fenretinide. J. Control. Release 287, 12\u201323. https:\/\/doi.org\/10.1016\/j.jconrel.2018.08.012 (2018).","journal-title":"J. Control. Release"},{"key":"22302_CR51","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s12951-021-01058-1","volume":"19","author":"X Yao","year":"2021","unstructured":"Yao, X. et al. Simvastatin induced ferroptosis for triple-negative breast cancer therapy. J. Nanobiotechnol. 19, 311. https:\/\/doi.org\/10.1186\/s12951-021-01058-1 (2021).","journal-title":"J. Nanobiotechnol."},{"key":"22302_CR52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12951-021-01205-8","volume":"20","author":"Z Yu","year":"2022","unstructured":"Yu, Z. et al. Nano delivery of simvastatin targets liver sinusoidal endothelial cells to remodel tumor microenvironment for hepatocellular carcinoma. J. Nanobiotechnol. 20, 9. https:\/\/doi.org\/10.1186\/s12951-021-01205-8 (2022).","journal-title":"J. Nanobiotechnol."},{"key":"22302_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121563","volume":"616","author":"FA Bruinsmann","year":"2022","unstructured":"Bruinsmann, F. A. et al. Nose-to-brain delivery of simvastatin mediated by chitosan-coated lipid-core nanocapsules allows for the treatment of glioblastoma in vivo. Int. J. Pharm. 616, 121563. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.121563 (2022).","journal-title":"Int. J. Pharm."},{"key":"22302_CR54","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jconrel.2022.04.017","volume":"346","author":"P Dehghankelishadi","year":"2022","unstructured":"Dehghankelishadi, P. et al. Formulation of simvastatin within high density lipoprotein enables potent tumour radiosensitisation. J. Control Release 346, 98\u2013109. https:\/\/doi.org\/10.1016\/j.jconrel.2022.04.017 (2022).","journal-title":"J. Control Release"},{"key":"22302_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.870347","author":"G Negrea","year":"2022","unstructured":"Negrea, G. et al. Active tumor-targeting nano-formulations containing simvastatin and doxorubicin inhibit melanoma growth and angiogenesis. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2022.870347 (2022).","journal-title":"Front. Pharmacol."},{"key":"22302_CR56","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1126\/science.1252787","volume":"343","author":"S Silvente-Poirot","year":"2014","unstructured":"Silvente-Poirot, S. & Poirot, M. Cancer. Cholesterol and cancer, in the balance. Science 343, 1445\u20131446. https:\/\/doi.org\/10.1126\/science.1252787 (2014).","journal-title":"Science"},{"key":"22302_CR57","doi-asserted-by":"publisher","first-page":"e2105126","DOI":"10.1002\/advs.202105126","volume":"9","author":"H Li","year":"2022","unstructured":"Li, H. et al. CRISPR\/Cas9 screens reveal that hexokinase 2 enhances cancer stemness and tumorigenicity by activating the acsl4-fatty acid beta-oxidation pathway. Adv. Sci. (Weinh) 9, e2105126. https:\/\/doi.org\/10.1002\/advs.202105126 (2022).","journal-title":"Adv. Sci. (Weinh)"},{"key":"22302_CR58","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nm.4055","volume":"22","author":"R Camarda","year":"2016","unstructured":"Camarda, R. et al. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat. Med. 22, 427\u2013432. https:\/\/doi.org\/10.1038\/nm.4055 (2016).","journal-title":"Nat. Med."},{"key":"22302_CR59","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.7150\/thno.82920","volume":"13","author":"K Yang","year":"2023","unstructured":"Yang, K. et al. The role of lipid metabolic reprogramming in tumor microenvironment. Theranostics 13, 1774\u20131808. https:\/\/doi.org\/10.7150\/thno.82920 (2023).","journal-title":"Theranostics"},{"key":"22302_CR60","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/ni.1937","volume":"11","author":"SK Biswas","year":"2010","unstructured":"Biswas, S. K. & Mantovani, A. Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat. Immunol. 11, 889\u2013896. https:\/\/doi.org\/10.1038\/ni.1937 (2010).","journal-title":"Nat. Immunol."},{"key":"22302_CR61","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13058-018-1066-z","volume":"20","author":"CH Beckwitt","year":"2018","unstructured":"Beckwitt, C. H., Brufsky, A., Oltvai, Z. N. & Wells, A. Statin drugs to reduce breast cancer recurrence and mortality. Breast Cancer Res. 20, 144. https:\/\/doi.org\/10.1186\/s13058-018-1066-z (2018).","journal-title":"Breast Cancer Res."},{"key":"22302_CR62","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1200\/JCO.2016.71.8981","volume":"35","author":"SB Larsen","year":"2017","unstructured":"Larsen, S. B. et al. Postdiagnosis statin use and mortality in Danish patients with prostate cancer. J. Clin. Oncol. 35, 3290\u20133297. https:\/\/doi.org\/10.1200\/JCO.2016.71.8981 (2017).","journal-title":"J. Clin. Oncol."},{"key":"22302_CR63","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.20222","volume":"6","author":"MS Vell","year":"2023","unstructured":"Vell, M. S. et al. Association of statin use with risk of liver disease, hepatocellular carcinoma, and liver-related mortality. JAMA Netw. Open. 6, e2320222. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.20222 (2023).","journal-title":"JAMA Netw. Open."},{"key":"22302_CR64","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s41564-023-01363-5","volume":"8","author":"JX Han","year":"2023","unstructured":"Han, J. X. et al. Microbiota-derived tryptophan catabolites mediate the chemopreventive effects of statins on colorectal cancer. Nat. Microbiol. 8, 919\u2013933. https:\/\/doi.org\/10.1038\/s41564-023-01363-5 (2023).","journal-title":"Nat. Microbiol."},{"key":"22302_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030062","volume":"7","author":"EA Mostaghel","year":"2012","unstructured":"Mostaghel, E. A., Solomon, K. R., Pelton, K., Freeman, M. R. & Montgomery, R. B. Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLoS ONE 7, e30062. https:\/\/doi.org\/10.1371\/journal.pone.0030062 (2012).","journal-title":"PLoS ONE"},{"key":"22302_CR66","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1634\/theoncologist.11-3-306","volume":"11","author":"K Hindler","year":"2006","unstructured":"Hindler, K., Cleeland, C. S., Rivera, E. & Collard, C. D. The role of statins in cancer therapy. Oncologist 11, 306\u2013315. https:\/\/doi.org\/10.1634\/theoncologist.11-3-306 (2006).","journal-title":"Oncologist"},{"key":"22302_CR67","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2174\/156800905774932824","volume":"5","author":"J Dulak","year":"2005","unstructured":"Dulak, J. & Jozkowicz, A. Anti-angiogenic and anti-inflammatory effects of statins: Relevance to anti-cancer therapy. Curr. Cancer Drug. Targets 5, 579\u2013594. https:\/\/doi.org\/10.2174\/156800905774932824 (2005).","journal-title":"Curr. Cancer Drug. Targets"},{"key":"22302_CR68","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2012.10.005","volume":"144","author":"S Singh","year":"2013","unstructured":"Singh, S., Singh, P. P., Singh, A. G., Murad, M. H. & Sanchez, W. Statins are associated with a reduced risk of hepatocellular cancer: A systematic review and meta-analysis. Gastroenterology 144, 323\u2013332. https:\/\/doi.org\/10.1053\/j.gastro.2012.10.005 (2013).","journal-title":"Gastroenterology"},{"key":"22302_CR69","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1002\/pros.21131","volume":"70","author":"A Parikh","year":"2010","unstructured":"Parikh, A. et al. Statin-induced autophagy by inhibition of geranylgeranyl biosynthesis in prostate cancer PC3 cells. Prostate 70, 971\u2013981. https:\/\/doi.org\/10.1002\/pros.21131 (2010).","journal-title":"Prostate"},{"key":"22302_CR70","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","volume":"88","author":"CR Sirtori","year":"2014","unstructured":"Sirtori, C. R. The pharmacology of statins. Pharmacol. Res. 88, 3\u201311. https:\/\/doi.org\/10.1016\/j.phrs.2014.03.002 (2014).","journal-title":"Pharmacol. Res."},{"key":"22302_CR71","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/jps.2600800905","volume":"80","author":"AT Serajuddin","year":"1991","unstructured":"Serajuddin, A. T., Ranadive, S. A. & Mahoney, E. M. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J. Pharm. Sci. 80, 830\u2013834. https:\/\/doi.org\/10.1002\/jps.2600800905 (1991).","journal-title":"J. Pharm. Sci."},{"key":"22302_CR72","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/j.2042-7158.2010.01030.x","volume":"62","author":"T Loftsson","year":"2010","unstructured":"Loftsson, T. & Brewster, M. E. Pharmaceutical applications of cyclodextrins: Basic science and product development. J. Pharm. Pharmacol. 62, 1607\u20131621. https:\/\/doi.org\/10.1111\/j.2042-7158.2010.01030.x (2010).","journal-title":"J. Pharm. Pharmacol."},{"key":"22302_CR73","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","volume":"80","author":"PJ Neuvonen","year":"2006","unstructured":"Neuvonen, P. J., Niemi, M. & Backman, J. T. Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. Clin. Pharmacol. Ther. 80, 565\u2013581. https:\/\/doi.org\/10.1016\/j.clpt.2006.09.003 (2006).","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22302-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22302-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22302-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T22:01:42Z","timestamp":1762207302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22302-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["22302"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-22302-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"7 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38430"}}